author-photo

Pietro Sozzi

18

Papers

418

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (1)
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

2019 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (7)
A3Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (20)
2*Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
D09Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (86)
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

2015 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (28)
Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

2001 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (19)